Viking Systems: Implementing a Public Start-Up Model
A year ago, Viking Systems Inc. reinvented itself based on the belief that it has found a way to take advantage of the public model to acquire small medical device companies and provide incentives to their entrepreneurial founders to work towards the greater good of an integrated company.
Viking will use combinations of stock, cash, and royalties tied to the future performance of products to acquire companies, products or services for the surgical suite that have strong intellectual property and revenues in the $500,000 to $10 million range. The idea is to take advantage of the medical device industry's fragmentation, both in terms of the large number of one-product companies that exist, and the requirement, in Viking's new target market-minimally invasive surgery--for numerous parts and pieces found within different types of companies. Its first acquisition was the visualization business of Vista Medical Technologies.
A year ago, Viking Systems Inc.
reinvented itself based on the belief that it has found a way to
take advantage of the public model to acquire small medical device
companies and provide incentives to their entrepreneurial founders
to work towards the greater good of an integrated company.
The firm had originally gone public in 2000 in a business that had nothing to do with health care; it was developing software and leasing hardware. It discontinued those operations...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.
The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.
Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.
Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.
Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
